Leukemia Research
Volume 27, Issue 9 , Pages 853-857 , September 2003

Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications

  • Farhad Ravandi

      Affiliations

    • Department of Hematology/Oncology, University of Illinois at Chicago, 840 South Wood Street, MC 787, Chicago, IL 60612-7323, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-312-996-5982; fax: +1-312-413-4131.
    • ,
  • Amit Verma

      Affiliations

    • Department of Hematology/Oncology, University of Illinois at Chicago, 840 South Wood Street, MC 787, Chicago, IL 60612-7323, USA
    • ,
  • Jean Ridgeway

      Affiliations

    • Department of Hematology/Oncology, University of Illinois at Chicago, 840 South Wood Street, MC 787, Chicago, IL 60612-7323, USA
    • ,
  • Kenneth Pursell

      Affiliations

    • Department of Infectious Diseases, University of Illinois at Chicago, Chicago, IL, USA

Received 7 October 2002 ,Accepted 13 December 2002.

References 

  1. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin. Oncol. 1998;25:11–18
  2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig (VH) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854
  3. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023–1029
  4. Ibrahim S, Keating M, Do KA, O’Brien S, Huh YO, Jilani I, et al.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181–186
  5. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl. J. Med. 2000;343:1910–1916
  6. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847
  7. Reed JC. Molecular biology of chronic lymphocytic leukemia: implications for therapy. Semin. Hematol. 1998;35:3–13
  8. Kipps TJ, Chu P, Wierda WG. Immunogenetic therapy for B-cell malignancies. Semin. Oncol. 2000;27:104–109
  9. Ghia P, Caligaris-Cappio F. The origin and nature of the chronic lymphocytic leukemia lymphocyte. In: Cheson BD, editor, Chronic lymphoid leukemias. 2nd ed. New York, Basel: Marcl Dekker; 2001. p. 63–80.
  10. Pizzolo G, Chilosi M, Ambrosetti A, Semenzato G, Fiore-Donati L, Perona G. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood. 1983;62:1289–1296
  11. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 1999;106:995–1004
  12. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, et al.  Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood. 1998;92:990–995
  13. Krammer PH. CD95’s deadly mission in the immune system. Nature. 2000;407:789–795
  14. Osorio LM, Aguilar-Santelises M. Apoptosis in B-chronic lymphocytic leukaemia. Med. Oncol. 1998;15:234–240
  15. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br. J. Haematol. 1997;97:409–417
  16. Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia. 1995;9:1227–1232
  17. Chu P, Wierda WG, Kipps TJ. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood. 2000;95:3853–3858
  18. Cloyd MW, Chen JJ, Adeqboyega P, Wang L. How does HIV cause depletion of CD4 lymphocytes? A mechanism involving virus signaling through its cellular receptors. Curr. Mol. Med. 2001;1:545–550
  19. Levine AM, Scadden DT, Zaia JA, Krishnan A. Hematologic aspects of HIV/AIDS. Hematology (Am Soc Hematol Educ Prog) 2001;463–78.
  20. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 2001;1:75–82
  21. Klein G, Klein E. Epstein-Barr virus and human lymphomas. In: Canellos GP, Lister TA, Sklar JL, editors. The lymphomas. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: Saunders; 1998. p. 63–73.
  22. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin. Oncol. 2000;27:390–401
  23. Knowles DM, Chamulak GA, Subar M, Burke JS, Dugan M, Wernz J, et al.  Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981–1986). Ann. Intern Med. 1988;108:744–753
  24. Kaplan MH, Susin M, Pahwa SG, Fetten J, Allen SL, Lichtman S, et al.  Neoplastic complications of HTLV-III infection. Lymphomas and solid tumors. Am. J. Med. 1987;82:389–396
  25. Analo HI, Akanmu AS, Akinsete I, Njoku OS, Okany CC. Seroprevalence study of HTLV-1 and HIV infection in blood donors and patients with lymphoid malignancies in Lagos, Nigeria. Cent. Afr. J. Med. 1998;44:130–134
  26. Rossi P, Carbonari M, Bonomo R, Galli M, Manconi PE, Scarpati B, et al.  Epidemiological aspects of HTLV-III infection in Italy. Eur. J. Epidemiol. 1985;1:288–293
  27. Levine AM, Sadeghi S, Espina B, Tulpule A, Nathwani B. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. Cancer. 2002;94:1500–1506

PII: S0145-2126(03)00004-3

doi: 10.1016/S0145-2126(03)00004-3

Leukemia Research
Volume 27, Issue 9 , Pages 853-857 , September 2003

Article Tools

* Image Usage & Resolution